The National Institute for Clinical Excellence's next work programme will consider of treatments for cancer and heart disease. Thrombolytic drugs for heart attacks, caelyx for ovarian cancer and STI-571 for chronic myeloid leukaemia will be appraised. Other treatments NICE will consider in the next wave will include surgical procedures for obesity and computerised cognitive behaviour therapy for people with anxiety and depression. It will also extend its evaluation of the rheumatoid arthritis drug etanercept to include children.
Related articles
-
NewsNICE calls to slash transfat levels
Small changes to people’s diets that make them more healthy could prevent tens of thousands of deaths each year from heart disease and stroke, experts have claimed.
-
HSJ PartnersUnlocking innovation in cancer care: A call to action for system-level change (AstraZeneca sponsored)
At a recent AstraZeneca UK sponsored HSJ roundtable event for NHS stakeholders, I had the privilege of hearing directly from clinicians, digital leads, and operational decision-makers across multiple cancer pathways.
-
HSJ AwardsHSJ Digital Awards 2025: Driving Change Through Data and Analytics Award
WINNER East of England Cancer Alliance: Closing The Gap on Cancer Waits in the East of England
More from Home
-
CommentHSJ introduces new rules for reader comments
HSJ is blessed with a very engaged readership. Each month our stories receive between 1,000-1,500 comments in total. This level of response is an order of magnitude greater than that enjoyed by most specialist titles.
-
NewsHelp accessing hsj.co.uk
We are aware that some of our users are experiencing problems accessing hsj.co.uk.
-
NewsImportant changes to your HSJ password
To protect your security as hsj.co.uk upgrades to a new platform, your existing password will no longer work.
No comments yet